ArticleMacromolecular bioscience2025
Immiscible Phase Separation-Driven Microfabrication of Gelatin Methacryloyl Scaffolds for BMP-2 Delivery and Osteogenic Enhancement.
Article in Macromolecular bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Design and Characterization of Gelatin-Based Interpenetrating Polymer Networks for Biomedical Use: Rheological, Thermal, and Physicochemical Evaluation.Materials (Basel, Switzerland) · 2026Article
- Immiscible Phase Separation-Driven Microfabrication of Gelatin Methacryloyl Scaffolds for BMP-2 Delivery and Osteogenic Enhancement.Macromolecular bioscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Gelatin methacryloyl (GelMA) hydrogels are recognized for their biocompatibility, tunable mechanics, and ability to support cellular functions, making them attractive for tissue engineering. However, achieving uniform, structurally stable micro-scaffolds for minimally invasive delivery remains challenging. Injectable hydrogels provide targeted delivery but lack the micro-architectural complexity required for effective regeneration, while 3D printing offers precision yet faces resolution, handling, and mechanical limitations. To overcome these barriers, we developed injectable GelMA micro-scaffolds (mS-GelMA) with controlled porosity, stability, and reproducibility using stop-flow lithography (SFL). This technique enables precise control over shape, porosity, and degradation, surpassing conventional injection moulding and 3D bioprinting in micro-particle uniformity and reproducibility. Scaffold performance was optimized by incorporating trimethylolpropane triacrylate (TMPTA) into GelMA, enhancing drug delivery and regenerative potential. Cellular assays confirmed high biocompatibility and functionality, with human mesenchymal stem cells (hMSCs) exhibiting excellent viability, migration, and osteogenic differentiation within the mS-GelMA scaffolds. These findings demonstrate that SFL-fabricated GelMA scaffolds bridge the gap between injectability and structural complexity, offering a promising platform for minimally invasive tissue engineering. This work highlights the potential of SFL-engineered hydrogels to advance scaffold-based regenerative medicine by combining architectural precision, biological performance, and clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.